Sorrento Therapeutics (SRNE)
(Delayed Data from OTC)
$0.01 USD
0.00 (25.00%)
Updated Sep 20, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
SRNE 0.01 0.00(25.00%)
Will SRNE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SRNE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRNE
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
SRNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
Other News for SRNE
Healthcare bankruptcies slow after peaking in 2023: report